MSB0010718C (avelumab) is a fully human IgG1 antibody targeting PD-L1 that is capable of mediating ADCC of tumor cells.15 A phase I dose escalation and expansion study of avelumab in 117 patients with advanced cancer has recently been completed at the NIH Clinical Center (NCT01772004). Here, CD274 is linked to cancer.